Journal article
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial
Xavier Castellsague, Jorma Paavonen, Unnop Jaisamrarn, Cosette M Wheeler, S Rachel Skinner, Matti Lehtinen, Paulo Naud, Song-Nan Chow, Maria Rowena Del Rosario-Raymundo, Julio C Teixeira, Johanna Palmroth, Newton S de Carvalho, Maria Julieta V Germar, Klaus Peters, Suzanne M Garland, Anne Szarewski, Willy AJ Poppe, Barbara Romanowski, Tino F Schwarz, Wiebren AA Tjalma Show all
BMC INFECTIOUS DISEASES | BMC | Published : 2014
Abstract
BACKGROUND: More information is needed about time between sexual initiation and human papillomavirus (HPV) infection and development of cervical precancer. METHODS: The objectives were to investigate the time between first sexual activity and detection of first cervical HPV infection or development of first cervical intraepithelial neoplasia (CIN), and associated factors in women from the double-blind, multinational, 4-year PATRICIA trial. PATRICIA enroled women aged 15-25 years with no more than 6 lifetime sexual partners. Women were randomized 1:1 to the HPV-16/18 AS04-adjuvanted vaccine or to control, but only women from the control arm who began sexual intercourse during the study or wit..
View full abstractGrants
Funding Acknowledgements
This work was supported by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis (ClinicalTrials.gov Identifier: NCT00122681). GlaxoSmithKline Biologicals SA also took in charge all costs associated with the development and the publishing of the present manuscript.-CERVARIX is a registered trademark of the GlaxoSmithKline group of companies.